Sotac Pharmaceuticals (NSE:SOTAC) Total Operating Expense: ₹242.5 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SOTAC Sotac Pharmaceuticals Ltd NSE:SOTAC
58 GF Score
Price ₹95.10
GF Value ₹140.82
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sotac Pharmaceuticals Total Operating Expense?

Sotac Pharmaceuticals NSE:SOTAC -4.90% 58 Total Operating Expense is ₹242.5 Mil as of Mar. 2026. GuruFocus rates NSE:SOTAC with a GF Score™ of 58/100 and a GF Value™ of ₹140.82 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Sotac Pharmaceuticals's Total Operating Expense for the six months ended in Mar. 2026 was ₹122.9 Mil. Sotac Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹242.5 Mil.

Sotac Pharmaceuticals Total Operating Expense Related Terms

Sotac Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Sotac Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals Total Operating Expense Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial 0.00 138.67 179.76 188.74 242.50

Sotac Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 80.20 84.13 104.61 119.61 122.89
NSE:SOTAC
58GF Score
Sotac Pharmaceuticals Ltd NSE:SOTAC
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sotac Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹242.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of ₹242.5 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Total Operating Expense of ₹242.5 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sotac Pharmaceuticals and its competitors.
Is Sotac Pharmaceuticals' Total Operating Expense too high?
Sotac Pharmaceuticals' current Total Operating Expense is ₹242.5 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Total Operating Expense compare to ZTS and UTHR?
Sotac Pharmaceuticals' Total Operating Expense of ₹242.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sotac Pharmaceuticals and its competitors. Sotac Pharmaceuticals's current Total Operating Expense is ₹242.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹140.82, compared to a current price of ₹95.10 — trading 32.5% below its estimated fair value. The current Total Operating Expense is ₹242.5 Mil. Sotac Pharmaceuticals' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Total Operating Expense is ₹242.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued. The current stock price of ₹95.10 is trading 32.5% below its estimated GF Value™ of ₹140.82. GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for NSE:SOTAC:

  • Total Operating Expense: ₹242.5 Mil
  • GF Value™: ₹140.82 vs. price of ₹95.10 (32.5% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotac Pharmaceuticals Business Description

Address Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
58GF Score

Get the complete analysis for NSE:SOTAC

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹95.10
Price
₹140.82
GF Value